Related Experiment Video
Updated: Jun 15, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery
Pavel Martinez-Dominguez1,2, Maria Jose Santa Ana-Bayona1, Enrique C Guerra1,3
1National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
Abstract:
Chemotherapy has markedly improved cancer outcomes, yet cancer therapy-related cardiac dysfunction (CTRCD) poses a significant challenge, affecting around 10% of patients. CTRCD can be asymptomatic or present with heart failure symptoms. Multimodality imaging, particularly echocardiography, remains pivotal for monitoring cardiac function. Potential biomarkers for CTRCD assessment include troponin and B-type natriuretic peptide. Pharmacological interventions, such as dexrazoxane, angiotensin-converting enzyme inhibitors, and statins, play a crucial role in primary prevention and mitigating cardiotoxicity alongside cardiac rehabilitation programs. Thus, a comprehensive approach is essential for optimal cardiac recovery and improved patient outcomes.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pathophysiology of Heart Failure
Tumor Immunotherapy

